Breast cancer and pregnancy: Diagnosis and treatment options

Breast Cancer Online

Volumn 12, Issue 7, 2009, Pages

  te Velde, E A ^a   Sonke, G ^a   Rutgers, E J Th ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; LUTEINIZING HORMONE DERIVATIVE; PROGESTERONE RECEPTOR; TAMOXIFEN; TECHNETIUM 99M;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER GRADING; CANCER HORMONE THERAPY; CASE REPORT; CONTRAST ENHANCEMENT; ECHOMAMMOGRAPHY; FEMALE; FIRST TRIMESTER PREGNANCY; GENETIC COUNSELING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MASTECTOMY; PATIENT REFERRAL; PREGNANCY; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 70349173440     PISSN: 14709031     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1470903109990198     Document Type: Article

References (14)

1. Petrek JA, Moore A. Breast cancer treatment in pregnant or postpartum women and subsequent pregnancy in breast cancer survivors In: Harris JR, Lippman ME, Morrow M, Osborne CK (Eds.). Diseases of the Breast, 3rd edition. Philadelphia, USA: Lippincott Williams and Wilkins, 2004: 691-701.
2. Mazze RI, Kallen B. Reproductive outcome after anaesthesia and operation during pregnancy: A registry study of 5405 cases. Am J Obstet Gynecol 1989; 161: 1178-1185.
3. Bollet MA, Sigal-Zafrani B, Mazeau V, et al. Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiother Oncol 2007; 82(3): 272-280.
4. Kreike B, Hart AA, van de Velde T, et al. Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up. Int J Radiat Oncol Biol Phys 2008; 71(4): 1014-1021.
5. Vrieling C, Collette L, Fourquet A, et al. EORTC Radiotherapy, Breast Cancer Groups. Can patient-, treatment-and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer 2003; 39(7): 932-944.
6. Antypas C, Sandilos P, Kouvaris J. Fetal dose evaluation during breast cancer radiotherapy. Int J Radiat Oncol Biol Phys 1998; 40: 995-999.
7. Navrozoglou I, Vrekoussis T, Kontostolis E, et al. Breast cancer during pregnancy: A mini-review. Eur J Surg Oncol 2008; 34: 837-843.
8. Gentilini O, Masullo M, Rotmensz N, et al. Breast cancer diagnosed during pregnancy and lactation: Biological features and treatment options. Eur J Surg Oncol 2005; 31(3): 232-236.
9. Pandit-Taskar N, Dauer LT, Montgomery L, St Germain J, Zanzonico PB, Divgi CR. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med 2006; 47(7): 1202-1208.
10. Valdés-Olmos RA, Jansen L, Hoefnagel CA, et al. Evaluation of mammary lymphoscintigraphy by a single intratumoral injection for sentinel node identification. J Nucl Med 2000; 41(9): 1500-1506.
11. Scherer K, Studer W, Figueiredo V, Bircher AJ. Anaphylaxis to isosulfan blue and cross-reactivity to patent blue V: Case report and review of the nomenclature of vital blue dyes. Ann Allergy Asthma Immunol 2006; 96(3): 497-500.
12. Lenhard MS, Bauerfeind I, Untch M. Breast cancer and pregnancy: challenges of chemotherapy. Crit Rev Oncol Hematol 2008; 67 3): 196-203.
13. Barthelmes L, Gateley CA. Tamoxifen and pregnancy. Breast 2004; 13: 446-451.
14. Bueno-de-Mesquita JM, Linn SC, Keijzer R, et al. Validation of 70-gene signature in node-negative breast cancer. Breast cancer Res Treat 2008 (in press).